Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Innocell in Recurrent Epithelial Ovarian Cancer
NCT06366490Phase 1Recruiting
- Sponsor
- PhotonPharma
- Start
- Feb 2026
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Innocell in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by PhotonPharma. Primary endpoints: Success rate of autologous manufacturing at 2 months and Safety assessed by treatment emergent adverse events. Started Feb 2026; status: recruiting.
02
Drugs
Innocell
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06366490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366490.